---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-066248"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2023-11-28T23:59:59+00:00"
generated_at: "2026-06-07T21:10:42.760924+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Candel Therapeutics announces 50% workforce reduction, restructuring to focus on CAN-3110 and enLIGHTEN platform

## Summary
- Approximately 50% workforce reduction; one-time restructuring charge of ~$0.7M in Q4 2023.
- Cash runway extended into Q4 2024; company prioritizes CAN-3110 development and enLIGHTEN platform.
- Key CAN-2409 readouts in 2024: NSCLC overall survival (Q2), pancreatic interim (Q2), prostate (Q4).
- Company will explore partnering opportunities for CAN-2409 to reduce commercial manufacturing costs.
- Initial CAN-3110 repeated injection data in recurrent high-grade glioma expected H2 2024; new enLIGHTEN data Q3 2024.

## SEC filing metadata
- accession: 0000950170-23-066248
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2023-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017023066248/0000950170-23-066248-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017023066248/cadl-20231126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-066248
- JSON: https://secwatch.observer/filing/0000950170-23-066248.json
- Plain text: https://secwatch.observer/filing/0000950170-23-066248.txt

## Key facts
- Restructurings & Charges
  Candel Therapeutics, Inc. announced a restructuring with charges of approximately $0.7 million affecting the Company (approximately 50%).
  - Type: restructuring
  - Charge: approximately $0.7 million
  - Affected area: the Company
  - Headcount: approximately 50%
  source text: On November 26, 2023, the Board of Directors (the “Board”) of Candel Therapeutics, Inc (the "Company") approved a strategic restructuring to focus on continuation and expansion of development of CAN-3110 as well as the enLIGHTEN TM Discovery Platform, and reducing the Company’s workforce by approximately 50%, as well as reducing expenses associated with enabling commercial readiness of CAN-2409, while maintaining and prioritizing key clinical readouts in 2024 (the “Restructuring Plan”). In connection with the Restructuring Plan, the Company estimates that it will incur a one-time restructuring charge of approximately $0.7 million in the fourth quarter of 2023 related to severance and healthcare and related benefits costs.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1841387/000095017023066248/0000950170-23-066248-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.